
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is a biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, particularly in the area of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The recent successful Part 2 maintenance readout for its lead drug candidate, obefazimod, reinforces its best-in-class efficacy and further removes previous concerns about malignancy risks. Despite a recent stock price increase, the company's significant financial runway and upcoming catalysts, including the presentation of full Part 1 UC maintenance data and potential partnership opportunities, provide significant upside potential for investors.
Bears say
Abivax is focused solely on the research and development of obefazimod, an oral therapy for inflammatory bowel diseases, with a projected topline for its Phase 3 trial in ulcerative colitis pushed to mid-2027 due to competitive enrollment processes. However, the extended runway provides an opportunity for the company to broaden the study, potentially enhancing its quality and positioning obefazimod as an early treatment option for IBD. And, lack of correlation between non-melanoma skin cancers (NMSCs) and skin lesions provides further reassurance about the safety of the drug in this regard.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares